The company has not filed an annual or quarterly report since its FY2020 10-K, filed Mar 22, 2021. Its latest SEC filing is a SC 13G/A from Feb 15, 2022.
10-K for FY2020, filed Mar 22, 2021
The sections below describe the company as of the FY2020 annual report.
Develops immune-modulating and targeted cancer therapies for patients with solid tumors, including antibody drug candidates for gastric and other cancers.
10-K for FY2020, filed Mar 22, 2021Our CompanyView ↗
Bemarituzumab (FPA144) is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, and that induces antibody-dependent…View ↗
FPT155 is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that we are studying in a clinical trial in…View ↗
FPA157 is an anti-CCR8 antibody that is engineered to deplete CCR8-expressing intratumoral regulatory CD4+ T cells. We are conducting…View ↗
Partners and licensees pay upfront and license fees, fund or reimburse research and development, and may pay milestone amounts when specified development or commercial events occur. The company also receives royalties when licensed products are sold.
10-K for FY2020, filed Mar 22, 2021
10-K for FY2020, filed Mar 22, 2021
FY2020 revenue by product or service ↗$13.2M
10-K for FY2020, filed Mar 22, 2021
$13.2M ↗| Segment | Share | Revenue |
|---|---|---|
|
Collaboration revenue
|
62% |
Collaboration revenue, FY2020
$8.2M Sources
|
|
License revenue
|
38% |
License revenue, FY2020
$5M Sources
|
Biotechnology and pharmaceutical companies partner with Five Prime through license and collaborative research and development agreements.
10-K for FY2020, filed Mar 22, 2021We have two late-stage research programs. These programs arose from our prior in-house target discovery and validation and protein…View ↗
Establish strategic license agreements and product and clinical collaborations to supplement our development capabilities and generate…View ↗
The terms of our license and collaborative research and development agreements include upfront and license fees, research, development and…View ↗
No. It lost $84.3M in FY2020.
10-K for FY2020, filed Mar 22, 2021
−$92.9MView ↗
10-K for FY2020, filed Mar 22, 2021
−$84.3MView ↗
10-K for FY2020, filed Mar 22, 2021
−$64.7MView ↗
8-K, filed Apr 16, 2021
The aggregate consideration to be paid by Purchaser to complete the Offer and the Merger is approximately $1.9 billion, without giving…View ↗
8-K, filed Apr 15, 2021
On April 15, 2021, the U.S. Food and Drug Administration (the “FDA”) notified Five Prime Therapeutics, Inc. (“Five Prime”) that the FDA has…View ↗
Shrank. Revenue fell 57% in 4 years, from $30.7M in FY2016 to $13.2M in FY2020, about 19% a year.
Narrower focus on cancer
The earlier report described a focus on discovering and developing protein therapies for serious diseases, including immuno-oncology; the latest report focuses on immune-modulating and targeted therapies for solid tumor cancers.
10-K for FY2017, filed Feb 27, 2018 10-K for FY2020, filed Mar 22, 2021We are a clinical-stage biotechnology company focused on discovering and developing innovative protein therapeutics to improve the lives of…View ↗
We are a clinical-stage biotechnology company focused on developing immune modulators and precision therapies to improve the lives of…View ↗
In-house discovery capabilities ended
The earlier report described an active target-discovery platform and plans to discover new candidates; the latest report says the company eliminated those in-house discovery and protein-engineering capabilities and plans to advance research programs mainly through outside contractors.
10-K for FY2017, filed Feb 27, 2018 10-K for FY2020, filed Mar 22, 2021
Loading...
